The Prostate Cancer Working Group 3 (PCWG3) defines progression based on three criteria: biochemical [prostate-specific antigen (PSA) increase ≥ 25% and ≥ 2 ng/mL above nadir], radiographic (per RECIST criteria), or clinical (worsening pain or quality of life)[10]. The gene discussed is KLK3; the disease is prostate carcinoma.